Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncophage route of administration in metastatic renal cell carcinoma
NCT00082459Phase 2Terminated
- Sponsor
- Agenus Inc.
- Start
- Jul 2002
- Primary completion
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vitespen in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Agenus Inc. Primary endpoints: Safety of HSPPC-96 and Tumor Response. Started Jul 2002; status: terminated.
02
Drugs
vitespen
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00082459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082459.